Home › NDC Lookup › Ingredients › Sodium Chloride › 00264-5802-00
Sodium Chloride .9 g/100mL Injection, Solution — NDC 00264-5802-00 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Sodium Chloride .9 g/100mL Injection, Solution — NDC 0264-5802-00 (Billing 00264-5802-00)

by B. Braun Medical Inc. · 12 CONTAINER in 1 CASE / 1000 mL in 1 CONTAINER

This is a package of Sodium Chloride .9 g/100mL Injection, Solution from B. Braun Medical Inc., marketed since Mar 1998 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.

NDC 00264-5802-00
🏷️ FDA NDC (as labeled) 0264-5802-00 billing pads the labeler segment with a zero
This package
Contains1000 mL in 1 container Medicaid pays$0.0574 / unit · 12 mo Per package$688.80 / 12000 ml · Medicaid Pack sizes2 compare ↓
Also priced by: Part D plans $0.0121/unit — full pricing hub ↓
Main listing for product 0264-5802 · Also comes in: 500 ml 0264-5802-10
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0264-5802-00 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0264 labeler · 5802 product · 00 package
Package marketed since
Jan 26, 2022
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0264580200 2
Medicaid fills, this package
69,542 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Sodium Chloride (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class I · Aug 17, 2026 — Presence of particulate matter: Particulates identified as fiberglass (Baxter Healthcare Corporation) · FDA recall D-0849-2026
Class II · Apr 2, 2026 — Lack of Assurance of Sterility (Huons Co., Ltd.) · FDA recall D-0531-2026
Class II · Mar 11, 2026 — Lack of Assurance of Sterility (Fresenius Kabi USA, LLC) · FDA recall D-0427-2026
Class II · Mar 11, 2026 — Lack of Assurance of Sterility (Fresenius Kabi USA, LLC) · FDA recall D-0424-2026
Class II · Mar 11, 2026 — Lack of Assurance of Sterility (Fresenius Kabi USA, LLC) · FDA recall D-0432-2026
Class II · Mar 11, 2026 — Lack of Assurance of Sterility (Fresenius Kabi USA, LLC) · FDA recall D-0426-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Past resolved recalls for this product (5)
Class III · Aug 2, 2023 · Terminated — Labeling: Not Elsewhere Classified - the description, warnings, storage information and instructions for use are either missing or partially printed. (B. Braun Medical Inc.) · FDA recall D-1083-2023
Class II · Jul 5, 2023 · Terminated — Lack of assurance of sterility: bags have the potential to leak. (B. Braun Medical Inc.) · FDA recall D-0916-2023
Class II · Feb 10, 2023 · Completed — Lack of sterility assurance: Recall of certain batches of 0.9% Sodium Chloride for Injection USP in EXCEL¿ Plus IV Container product due to the possibility of an incomplete seal that may cause leakage. The impacted lots may exhibit microscopic channel leaks near the port assembly of the product. (B. Braun Medical Inc.) · FDA recall D-0346-2023
Class II · Feb 10, 2023 · Completed — Lack of sterility assurance: Recall of certain batches of 0.9% Sodium Chloride for Injection USP in EXCEL¿ Plus IV Container product due to the possibility of an incomplete seal that may cause leakage. The impacted lots may exhibit microscopic channel leaks near the port assembly of the product. (B. Braun Medical Inc.) · FDA recall D-0347-2023
Class II · Nov 25, 2022 · Terminated — Lack of sterility assurance: Bags have the potential to leak. (B. Braun Medical, Inc.) · FDA recall D-0076-2023

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0264-5802-00
Product NDC 0264-5802
11-digit billing NDC 00264580200
NCPDP billing unit ML — per mL (volume)
RxCUI 1807552, 1807634, 1807639
UNII 451W47IQ8X
Application # NDA019635
SPL Set ID e44c41ae-c9c8-4dd8-ba6c-cebb585378aa
Established class (EPC) Osmotic Laxative
Mechanism of action Osmotic Activity
Physiologic effect Increased Large Intestinal Motility; Inhibition Large Intestine Fluid/Electrolyte Absorption
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1998-03-09
Route INTRAVENOUS
Dosage form INJECTION, SOLUTION
Substance SODIUM CHLORIDE
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 79750010002021
GPI class Sodium Chloride
GCN Seq No 001210
GCN 02962
HICL code 008255
Ingredient (HICL) 0.9 % Sodium Chloride
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C1
Therapeutic class — intermediate (HIC2) Drugs Affecting Electrolyte Balance
HIC3 code C1B
Therapeutic class — specific (HIC3) Sodium/Saline Preparations
AHFS code 40:12.00.00
AHFS class Replacement Preparations
FDB label name SODIUM CHLORIDE 0.9% SOLUTION
FDB brand name Sodium Chloride
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 001210
  • GCN: 02962
  • GPI-14 (Medi-Span): 79750010002021
  • HICL (First Databank): 008255
  • AHFS class code: 40:12.00.00
  • RxCUI (RxNorm): 1807552
Why two NDCs? The FDA registers this code as 0264-5802-00 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00264-5802-00. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Sodium class.

Drug family (ATC) Sodium, Salt solutions, Electrolyte solutions
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name SODIUM CHLORIDE 0.9% SOLUTION Ingredient 0.9 % Sodium Chloride
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. IV forms replace fluid and salt, while injection diluents dissolve other drugs. Other forms are used for rinsing, nasal congestion and nasal care, or to...
  • Follow the directions on your product. Many are used as often as needed by adults and children 4 and over. Do not share the bottle, because that can spread infection.
  • Some people get fever, irritation or infection at the IV site, or too much fluid in the body. Tell your nurse right away if the IV site hurts or looks red.
  • What side effects should I expect with IV sodium chloride?
📖 Read our full Sodium Chloride guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $0.0574 $688.80 / 12000 ml
Medicare drug plans payPart D · Q2 2026 $0.0121 $145.20 / 12000 ml
Medicare Part B allowsASP · J7040 $1.350 / J7040 unit —
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)0264-5802-00
11-digit billing NDC00264-5802-00
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ7040
DescriptorINFUSION, NORMAL SALINE SOLUTION, STERILE (500 ML=1 UNIT)
Billing units / pkg0 units
How the units are derivedThis package is 1000 ML; the HCPCS unit is 500 ML, so one package = 0 billing units.
Medicare Part B spend (2026 (Q1))$60,184 · 40,325 claims · $1.49 per claim (all NDCs under J7040)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00264-5802-00 You're viewing this Main listing 12 CONTAINER in 1 CASE / 1000 mL in 1 CONTAINER 2022-01-26 — Active
00264-5802-10 0264-5802-10 24 CONTAINER in 1 CASE / 500 mL in 1 CONTAINER 2022-01-26 — Active

In Medicaid, this is the most-dispensed pack of this product — about 81% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 12 container in 1 case / 1000 ml in 1 container.
What NDC number is used to bill for this package of Sodium Chloride .9 g/100mL Injection, Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Sodium Chloride .9 g/100mLthis 00264-5802-00 B. 1000 ml — AP FDA listed —
Sodium Chloride .9 g/100mL 00264-7800-09 B. 1000 ml — AP FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1998
On the market since
Mar 1998
📍
2026
Currently FDA-listed
28 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerB. Braun Medical Inc.
Application holderB BRAUN MEDICAL INC
FDA applicationNDA019635 (NDA)
Labeler code00264
First marketedMar 1998
Product typeHuman Prescription Drug
Portfolio94 products on file

More NDCs from B. Braun Medical Inc. labeler code 00264

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 173 words ▾

INDICATIONS AND USAGE These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 0.9% Sodium Chloride Injection USP is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion. 0.9% Sodium Chloride Injection USP is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells.

0.45% Sodium Chloride Injection USP is primarily a hydrating solution and may be used to assess the status of the kidneys, since more water is provided than is required for excretion of salt. It may also be used in the treatment of hyperosmolar diabetes where the use of dextrose is inadvisable and there is a need for large amounts of fluid without an excess of sodium ions. Sodium Chloride Injections USP are also indicated as pharmaceutic aids and diluents for the infusion of compatible drug additives.

Refer to prescribing information accompanying additive drugs.

⏱️ Dosage and Administration 211 words ▾

DOSAGE AND ADMINISTRATION These solutions are for intravenous use only. Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

In the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of 0.9% sodium chloride (154 mEq each of sodium and chloride). There is no specific pediatric dose. The dose is dependent on weight, clinical condition and laboratory results.

Follow recommendations of appropriate pediatric reference text. (See PRECAUTIONS, Pediatric Use .) Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. 0.9% Sodium Chloride Injection USP may also be administered intravascularly as a priming fluid in hemodialysis procedures.

When Sodium Chloride Injections USP are used as diluents for infusion of compatible drug additives, refer to dosage and administration information accompanying additive drugs. Some additives may be incompatible. Consult with pharmacist.

When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

⛔ Contraindications 16 words ▾

CONTRAINDICATIONS These solutions are contraindicated where the administration of sodium or chloride could be clinically detrimental.

⚠️ Warnings 134 words ▾

WARNINGS The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Infusion of isotonic (0.9%) sodium chloride during or immediately after surgery may result in excessive sodium retention.

Use the patient's circulatory system status as a guide.

🤒 Adverse Reactions 177 words ▾

ADVERSE REACTIONS Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. Anaphylaxis has occasionally been reported. The physician should also be alert to the possibility of adverse reactions to drug additives.

Prescribing information for drug additives to be administered in this manner should be consulted. Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume.

Cerebral edema and myelinolysis have been reported. If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

🤰 Pregnancy 55 words ▾

Pregnancy: Teratogenic Effects Animal reproduction studies have not been conducted with Sodium Chloride Injections USP. It is also not known whether Sodium Chloride Injections USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injections USP should be given to a pregnant woman only if clearly needed.

🧒 Pediatric Use 56 words ▾

Pediatric Use Safety and effectiveness of sodium chloride injections in pediatric patients have not been established by adequate and well controlled trials, however, the use of electrolyte solutions in the pediatric population is referenced in the medical literature. The warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population.

🧓 Geriatric Use 113 words ▾

Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

🆘 Overdosage 22 words ▾

OVERDOSAGE In the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition and institute appropriate corrective treatment.

🧬 Clinical Pharmacology 100 words ▾

CLINICAL PHARMACOLOGY Sodium Chloride Injections USP provide electrolytes and are a source of water for hydration. They are capable of inducing diuresis depending on the clinical condition of the patient. Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids.

Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid. Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.

📦 How Supplied / Storage and Handling 86 words ▾

HOW SUPPLIED Sodium Chloride Injections USP are supplied sterile and nonpyrogenic in EXCEL ® Plus Containers. The 1000 mL containers are packaged 12 per case; the 500 mL containers are packaged 24 per case. NDC REF Size 0.9% Sodium Chloride Injection USP 0264-5802-00 Q8000 1000 mL 0264-5802-10 Q8001 500 mL 0.45% Sodium Chloride Injection USP 0264-5804-00 Q8020 1000 mL Store at 20 to 25°C (68 to 77°F); excursions permitted 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat.

Protect from freezing.

📦 Storage and Handling 27 words ▾

Store at 20 to 25°C (68 to 77°F); excursions permitted 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing.

📋 Description ~1 min read ▾

DESCRIPTION Each 100 mL of 0.9% Sodium Chloride Injection USP contains: Sodium Chloride USP 0.9 g; Water for Injection USP qs pH: 5.6 (4.5–7.0) Calculated Osmolarity: 308 mOsmol/liter pH adjusted with Hydrochloric Acid NF Concentration of Electrolytes (mEq/liter): Sodium 154 Chloride 154 Each 100 mL of 0.45% Sodium Chloride Injection USP contains: Sodium Chloride USP 0.45 g; Water for Injection USP qs pH: 5.6 (4.5–7.0) Calculated Osmolarity: 154 mOsmol/liter, hypotonic pH adjusted with Hydrochloric Acid NF Concentration of Electrolytes (mEq/liter): Sodium 77 Chloride 77 Sodium Chloride Injections USP are sterile, nonpyrogenic, isotonic and contain no bacteriostatic or antimicrobial agents.

The formula of the active ingredient is: Ingredient Molecular Formula Molecular Weight Sodium Chloride USP NaCl

58.44Not made with natural rubber latex, PVC or DEHP. The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables.

The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration.

The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. Addition of medication should be accomplished using complete aseptic technique. The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site.

Refer to the Directions for Use of the container.

💬 Information for Patients ~1 min read ▾

Directions for Use of EXCEL® Plus Container Caution: Do not use plastic containers in series connection. To Open Tear overwrap down at notch and remove solution container. Check for minute leaks by squeezing solution container firmly.

If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below before preparing for administration. NOTE : Before use, perform the following checks: Inspect each container.

Read the label. Ensure solution is the one ordered and is within the expiration date. Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter.

Any container which is suspect should not be used. Use only if solution is clear and container and seals are intact. Preparation for Administration Remove foil cover from sterile set port at bottom of container as shown in Figure A, Steps 1 and 2.

Attach administration set. Refer to complete directions accompanying set. To Add Medication Warning: Some additives may be incompatible.

To Add Medication Before Solution Administration Prepare medication site. Using syringe with 18–22 gauge needle, puncture medication port and inner diaphragm and inject. Squeeze and tap ports while ports are upright and mix solution and medication thoroughly.

To Add Medication During Solution Administration Close clamp on the set. Prepare medication site. Using syringe with 18–22 gauge needle of appropriate length (at least 5/8 inch), puncture resealable medication port and inner diaphragm and inject.

Remove container from IV pole and/or turn to an upright position. Evacuate both ports by tapping and squeezing them while container is in the upright position. Mix solution and medication thoroughly.

Return container to in use position and continue administration. Figure A - Step 1 Illustration Figure A - Step 2 Illustration

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require tailoring of the electrolyte pattern, in these or alternative solutions. These solutions should be used with care in patients with hypervolemia, renal insufficiency, urinary tract obstruction, or impending or frank cardiac decompensation.

Extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. Additional essential electrolytes, minerals and vitamins should be supplied as needed. Sodium-containing solutions should be administered with caution to patients receiving corticosteroids or corticotropin, or to other salt-retaining patients.

Care should be exercised in administering solutions containing sodium to patients with renal or cardiovascular insufficiency, with or without congestive heart failure, particularly if they are postoperative or elderly. Infusion of more than one liter of isotonic (0.9%) sodium chloride per day may supply more sodium and chloride than normally found in serum, and can exceed normal tolerance, resulting in hypernatremia; this may also cause a loss of bicarbonate ions, resulting in an acidifying effect. To minimize the risk of possible incompatibilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration and periodically during administration.

Do not use plastic containers in series connection. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. If administration is not controlled by a pumping device, refrain from applying excessive pressure (>300mmHg) causing distortion to the container such as wringing or twisting.

Such handling could result in breakage of the container. These solutions are intended for intravenous administration using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours.

Use only if solution is clear and container and seals are intact. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies with Sodium Chloride Injections USP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility. Pregnancy: Teratogenic Effects Animal reproduction studies have not been conducted with Sodium Chloride Injections USP.

It is also not known whether Sodium Chloride Injections USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injections USP should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk.

Because many drugs are excreted in human milk, caution should be exercised when Sodium Chloride Injections USP are administered to a nursing woman. Pediatric Use Safety and effectiveness of sodium chloride injections in pediatric patients have not been established by adequate and well controlled trials, however, the use of electrolyte solutions in the pediatric population is referenced in the medical literature. The warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population.

Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting t… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 37 words ▾

Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sodium Chloride Injections USP are administered to a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 25 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility Studies with Sodium Chloride Injections USP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

📄 Package Label / Principal Display Panel ~3 min read ▾

PRINCIPAL DISPLAY PANEL - 0.9 g/1000 mL Container Label 0.9% Sodium Chloride Injection USP REF Q8000 NDC 0264-5802-00 1000 mL EXCEL ® PLUS CONTAINER Each 100 mL contains: Sodium Chloride USP 0.9 g; Water for Injection USP qs pH adjusted with HCl NF pH: 5.6 (4.5-7.0); Calc. Osmolarity: 308 mOsmol/liter Electrolytes (mEq/liter): Na + 154; Cl – 154 Sterile, nonpyrogenic. Single-dose container.

Do not use in series connection. For intravenous use only. Use only if solution is clear and container and seals are intact.

WARNINGS: Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques.

Mix thoroughly. Do not store. Store at 20 to 25°C (68 to 77°F); excursions permitted 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat.

Protect from freezing. See Package Insert. Do not remove overwrap until ready for use.

After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. Not made with natural rubber latex, PVC or DEHP.

Rx only EXCEL is a registered trademark of B. Braun Medical Inc. B.

Braun Medical Inc. Bethlehem, PA 18018-3524 USA 1-800-227-2862 Y94-003-357 LD-630-1 EXP LOT Other 1000 mL Container Label Q8000

PRINCIPAL DISPLAY PANEL - 0.9 g/500 mL Container Label 0.9% Sodium Chloride Injection USP REF Q8001 NDC 0264-5802-10 500 mL EXCEL ® PLUS CONTAINER Each 100 mL contains: Sodium Chloride USP 0.9 g; Water for Injection USP qs pH adjusted with HCl NF pH: 5.6 (4.5–7.0); Calc. Osmolarity: 308 mOsmol/liter Electrolytes (mEq/liter): Na + 154; Cl – 154 Sterile, nonpyrogenic. Single-dose container.

Do not use in series connection. For intravenous use only. Use only if solution is clear and container and seals are intact.

WARNINGS: Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques.

Mix thoroughly. Do not store. Store at 20 to 25°C (68 to 77°F); excursions permitted 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat.

Protect from freezing. See Package Insert. Do not remove overwrap until ready for use.

After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. Not made with natural rubber latex, PVC or DEHP.

Rx only EXCEL is a registered trademark of B. Braun Medical Inc. B.

Braun Medical Inc. Bethlehem, PA 18018-3524 USA 1-800-227-2862 Y94-003-358 LD-631-1 EXP LOT Other 500 mL Container Label Q8001

PRINCIPAL DISPLAY PANEL - 0.45 g/1000 mL Container Label 0.45% Sodium Chloride Injection USP REF Q8020 NDC 0264-5804-00 1000 mL EXCEL ® PLUS CONTAINER Each 100 mL contains: Sodium Chloride USP 0.45 g; Water for Injection USP qs pH adjusted with HCl NF pH: 5.6 (4.5-7.0); Calc. Osmolarity: 154 mOsmol/liter, hypotonic Electrolytes (mEq/liter): Na + 77; Cl – 77 Sterile, nonpyrogenic. Single-dose container.

Do not use in series connection. For intravenous use only. Use only if solution is clear and container and seals are intact.

WARNINGS: Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques.

Mix thoroughly. Do not store. Store at 20 to 25°C (68 to 77°F); excursions permitted 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat.

Protect from freezing. See Package Insert. Do not remove overwrap until ready for use.

After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired. Not made with natural rubber latex, PVC or DEHP.

Rx only EXCEL is a registered trademark of B. Braun Medical Inc. B.

Braun Medical Inc. Bethlehem, PA 18018-3524 USA 1-800-227-2862 Y94-003-360 LD-632-1 EXP LOT Other 1000 mL Container Label Q8020

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
69.5K
Units reimbursed last 4 qtrs
73.5M
Gross reimbursed last 4 qtrs
$4.22M
Avg / prescription
$60.67
Avg / unit
$0.0574
Latest quarter Q4 2025
13.4KRx
Fee-for-service vs managed care ⓘ
94% MCO
Fee-for-service · 3,853 Rx Managed care · 65,689 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 45 units · 0.6 per 100k residents WA Idaho: 133,000 units · 6,772 per 100k residents ID Montana: 237,500 units · 20,981 per 100k residents MT North Dakota: no data reported ND Minnesota: 7,188,500 units · 125,301 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 11,628,850 units · 59,419 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 126,000 units · 2,977 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 45,001 units · 656 per 100k residents IN Ohio: 9,256,474 units · 78,545 per 100k residents OH Pennsylvania: 3,642,000 units · 28,100 per 100k residents PA New Jersey: 10,940,000 units · 117,761 per 100k residents NJ Massachusetts: 6,303 units · 90.0 per 100k residents MA California: 484,265 units · 1,243 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 16,000 units · 809 per 100k residents NE Missouri: 309,000 units · 4,987 per 100k residents MO Kentucky: 5,023,453 units · 110,991 per 100k residents KY West Virginia: 115,000 units · 6,497 per 100k residents WV Virginia: 5,516,123 units · 63,287 per 100k residents VA Maryland: 649,365 units · 10,508 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 127,000 units · 1,709 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 203,246 units · 2,852 per 100k residents TN North Carolina: 13,505,190 units · 124,644 per 100k residents NC South Carolina: 368,748 units · 6,863 per 100k residents SC Delaware: no data reported DE Oklahoma: 61,000 units · 1,505 per 100k residents OK Louisiana: 45,060 units · 985 per 100k residents LA Mississippi: 51,756 units · 1,760 per 100k residents MS Alabama: 14,014 units · 274 per 100k residents AL Georgia: 172,500 units · 1,564 per 100k residents GA D.C.: 884,507 units · 130,266 per 100k residents DC Hawaii: no data reported HI Texas: 317,000 units · 1,039 per 100k residents TX Florida: 2,469,705 units · 10,923 per 100k residents FL
Units reimbursed · per 100k residents
0.6130,266
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 D.C. 130,266 /100k
2 Minnesota 125,301 /100k
3 North Carolina 124,644 /100k
4 New Jersey 117,761 /100k
5 Kentucky 110,991 /100k
6 Ohio 78,545 /100k
7 Virginia 63,287 /100k
8 New York 59,419 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 ml this page00264-5802-00 69,542 Rx · $4,218,920
5 ml00264-5802-10 16,081 Rx · $1,245,881
Drug total (last 4 qtrs): 85,623 Rx · 83,999,779 units · $5,464,802 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Sodium Chloride — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Sodium Chloride. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.42M
Claims incl. refills
105K
Beneficiaries
50.3K
Spend / beneficiary
$48.15
Spend / claim
$23.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by B. Braun Medical Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 500 ml (00264-5802-10). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
B. Braun Medical Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J7040 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00264-5711-10 · B. 00264-5804-00 · B. →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.